Macrochem acquires option to license pexiganan

WELLESLEY HILLS, Mass., July 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTCBB: MACM - News) today announced that it has signed an exclusive option to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation (Genaera).

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials. It also fits our strategic focus and complements our lead product candidate, EcoNail(TM) for treatment of nail fungus currently in a fully enrolled Phase 2 trial and progressing on track with an interim assessment of clinical data later this year after all patients have been treated for twenty four weeks," said Robert J. DeLuccia, President and CEO of MacroChem.

Clinical trials with pexiganan previously conducted by Genaera include two Phase 3 trials submitted in a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 1998. At that time, outstanding issues with CMC (Chemistry, Manufacturing and Controls) and an FDA request for one additional controlled trial precluded approval.

Mr. DeLuccia further noted, "We would be pleased to have pexiganan in our hands since we believe that, if approved, it would be welcomed by physicians and patients for the treatment of diabetic foot infection. In recent years, there have been many advances in the manufacturing of peptides, a better understanding of the treatment of diabetic foot infection, improvements in clinical trial design and execution, and more clarity concerning regulatory requirements for topical anti-infectives with the potential market being even more attractive than before."

He added, "There continues to be a very large and growing incidence of diabetes and, as a result, a growing number of diabetic foot infections in the

Contact: Bill Douglass

Page: 1 2

Related biology news :

1. Biogen Idec acquires Brandeis spin-out
2. Wiley acquires publications from Carpe Diem Communications
3. Ossur hf. acquires the Gibaud Group in France
4. Springer acquires BioTribune Magazine and Biotribune.com
5. Stevens Davidson Laboratory acquires new research vessel
6. Accentia Biopharmaceuticals acquires exclusive license
7. Ossur acquires US orthotics company Royce Medical
8. Molecular Profiling Institute, Inc. acquires NanoBiomics, Inc.
9. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
10. Fat stem cells being studied as option for breast reconstruction
11. Drug offers new options for leukemia patients

Post Your Comments:

(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/18/2015)... ALBANY, New York , November 18, 2015 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2021. According to ... bn in 2014 and is anticipated to reach US$29.1 ... 2015 to 2021. North America ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... November 24, 2015 SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
(Date:11/24/2015)... SAN FRANCISCO , Nov. 24, 2015 /PRNewswire/ ... today announced that Emily Leproust, Ph.D., Twist Bioscience ... Piper Jaffray Healthcare Conference on December 1, 2015 ... Palace Hotel in New York City. ... www.twistbioscience.com . Twist Bioscience is on ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
Breaking Biology Technology:
Cached News: